Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Follicular Lymphoma Clinical Trials

A listing of Follicular Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (395) clinical trials

Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas

Subjects will receive doses of FF-10502-01 intravenously (IV) weekly for three weeks, repeated every 28 days (= 1 cycle). Disease assessments, based on computed tomography (CT), magnetic resonance image (MRI), and, for lymphoma, [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) scans, will be obtained at Week 8 and every 8 weeks thereafter ...


Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Study ADCT-402-101 is the first clinical study with ADCT-402 in patients with B-cell non-Hodgkin Lymphoma (NHL). ADCT-402 is an antibody drug conjugate (ADC) composed of a humanized antibody directed against human cluster of differentiation 19 (CD19), stochastically conjugated via a valine-alanine cleavable, maleimide linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. ...


Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma

Patients with advanced stage follicular lymphoma, untreated and relapsed are eligible for this study. Staging includes PET/CT, CT and bone marrow specimens. Lymphoma nodes must be available for surgical biopsy, radiation and intranodal treatment. Additionally, there must be evaluable lesions for measuring systemic effects. The patient undergo leukapheresis for collection ...


A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

SGN-CD19B will be given to patients at increasing doses every 28 days (or on an alternative dosing schedule of every 42 days). Individual expansion cohorts of up to approximately 20 patients will be opened at dose levels selected by the Safety Monitoring Committee based on the aggregate known safety and ...


PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

This is a first-in-human, multi-center, open-label clinical study with separate Dose Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of KPT-9274, a dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies (including sarcoma, colon, lung, etc.) or NHL for which all standard therapeutic options ...


Phase II Study of TAK228 in Relapsed Lymphoma

Study Drug Administration: If participant is found to be eligible for this study, they will begin taking capsules of TAK-228 in 28-day cycles. Participant will take the drug 1 time every day at about the same time. Participant should take the drug with about a cup (8 ounces) of water ...


Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma

This is a single-arm, multicenter Phase 2 study to evaluate the efficacy and safety of the CAR-T for Recurrent or refractory diffuse large B cell lymphoma.The study will be conducted using a phase I/II design. The study will have the following sequential phases: Part A (screening leukapheresis,cell product preparation, and ...

Phase N/A

A Study Evaluating Safety and Efficacy of Obinutuzumab Polatuzumab Vedotin (Pola) and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab Atezo and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of obinutuzumab + Atezo + Pola in participants with relapsed or refractory FL and rituximab + Atezo + Pola in participants with relapsed or refractory DLBCL. The study will include an initial dose-escalation phase designed to determine the recommended Phase ...


Transplantation of Ex Vivo Expanded UCB-derived Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients

Successful blood and marrow transplantation (BMT) requires the infusion of a sufficient number of hematopoietic stem/progenitor cells (HSPCs), capable of both homing to the bone marrow and regenerating a full array of hematopoietic cell lineages with early and late repopulating ability in a timely fashion. A major drawback of Umbilical ...


A Phase 1 Multiple Ascending Dose Study of DS-3201b in Japanese Subjects With Lymphomas

This will be a First-in-Human, Phase 1, multi-center, non-randomized, open label study of DS-3201b, Histone-lysine N-methyltransferase EZH1/2 dual inhibitor to assess its safety and tolerability, identify a maximum tolerated dose (MTD)/ tentative recommended phase 2 dose (RP2D), and assess its pharmacokinetic/dynamic properties in Japanese subjects with Non-Hodgkin's Lymphoma.